Pharmaceuticals and chemicals highlights to 09:10 GMT

Pharmaceuticals and chemicals highlights to 09:10 GMT

	Published : Fri, 19 Jan 2007 10:27 By : Agencies Print this Story

2007-01-19 08:00:18

Bayer Schering signs imaging compound deal with Taisho, Nihon Nohyaku

FRANKFURT (AFX) - Bayer Schering Pharma AG said it signed a licence and

option agreement with Taisho Pharmaceutical Co, Nihon Nohyaku Co, and the

National Institute of Radiological Sciences (NIRS) in Japan to develop imaging

compounds to detect neurodegenerative diseases including Alzheihmer's and

Parkinson's.

2007-01-19 07:51:58

Straumann bone graft products' US import licences suspended

ZURICH (AFX) - Straumann Holdings said dental bone grafting products

manufactured by its Sweden-based Biora unit have had their US import

authorisations suspended amid quality control and administrative concerns.

2007-01-19 07:45:55

Bayer Schering signs imaging compound licence agreement with Taisho, Nihon

FRANKFURT (AFX) - Bayer Schering Pharma AG said it has signed a licence and

option agreement with Taisho Pharmaceutical Co, Nihon Nohyaku Co, and the

National Institute of Radiological Sciences (NIRS) in Japan to develop imaging

compounds to detect neurodegenerative diseases including Alzheihmer's and

Parkinson's.

2007-01-19 07:21:14

Omega Pharma FY sales at top of estimates, Arseus spin-off 'on schedule'

BRUSSELS (AFX) - Belgian healthcare group Omega Pharma NV has posted a

trading update which shows full-year sales in line with the company's own

estimates of 1 bln eur, driven by growth in the Belgian over-the-counter market.

2007-01-19 07:20:44

Straumann bone graft products' US import licences suspended amid FDA concerns

ZURICH (AFX) - Straumann Holdings said dental bone grafting products

manufactured by its Sweden-based Biora unit have had their US import

authorisations suspended amid quality control and admininstrative concerns.

2007-01-19 07:05:04

Omega Pharma FY sales at top end of estimates, Arseus spin-off 'on schedule'

BRUSSELS (AFX) - Belgian healthcare group Omega Pharma NV has posted a

trading update which shows full-year sales in line with the company's own

estimates of 1 bln eur, driven by growth in the Belgian over-the-counter market.